American Epidemic: Diabetes Cases Soar by 50 Percent or More in 42 States
American Epidemic: Diabetes Cases Soar By 50 Percent Or More In 42 States
Filed under: drug treatment programs in west virginia
… and Alabama (up 140 percent). In West Virginia, where nearly 70 percent of residents are either overweight or obese, the number of people diagnosed with diabetes rose 131 percent. … But treatment can be cost-prohibitive. Drugs for pre-diabetic or …
Read more on ThinkProgress
CDC, Others Look at Antibiotic Resistance
Filed under: drug treatment programs in west virginia
The highest rates of prescribing were seen in Kentucky, West Virginia, Tennessee, Mississippi, and Louisiana, and the lowest were seen in Alaska, Hawaii, California, Oregon, and Washington. Other concerning findings included the declining effectiveness …
Read more on Everyday Health
Veterans Court starts in Brooke County
Filed under: drug treatment programs in west virginia
It's the first of its kind in West Virginia: Veterans Court. Its first … According to probation officer Steve Seminsky, the program does not give special treatment to veterans. Rather, it's similar to Drug Court, which is already in place, that gives …
Read more on WTOV Steubenville
Marshall University: MIIR Seminar Series, Blair Gibson – HUNTINGTON, W.Va. — The focus of a program that was presented by Blair Gibson, former executive director for Portfolio Strategy and Strategic Planning at Merck & Co., will be research and development productivity and opportunities for academic collaboration in the pharmaceutical industry. The event was hosted by the Marshall Institute for Interdisciplinary Research (MIIR), and took place Wednesday, Oct. 27, at Marshall University Foundation Hall, Home of the Erickson Alumni Center at 519 John Marshall Dr. in Huntington. Gibson, a Marshall University alumnus, has worked for some of the largest pharmaceutical companies in the world such as Merck & Co., Sanofi Aventis and Pharmacia (now Pfizer Inc.), and has more than 25 years of experience in the industry in both commercial and strategic planning roles. He headed the global launch of JANUVIA, a blockbuster drug for the treatment of type-2 diabetes. The launch of this drug was praised by the pharmaceutical industry as one of the best launches ever of a primary-care drug. Gibson’s work experience has been largely global in scope and he has even served expatriate assignments in Europe and Latin America. “We are very excited about having Blair present the lecture this fall. He has unique insight into areas of health and technology that affect our daily lives. Considering the changes ahead of us in health care, the timing of this lecture could not be better,” said Dr. Eric Kmiec, director of MIIR and the institute’s lead …